Cervical spinal cord injuries (SCI) frequently induce, in addition to para and tetraplegia, respiratory insufficiencies that constitute major complicating factors by increasing dependency (assisted ventilation) and probability of post-trauma death.

In order to counterbalance respiratory deleterious effects after cervical SCI, we tested the impact of intra-spinal transplantation of nasal olfactory ensheathing cells (OEC), a strategy considered as promising for spinal cord repair. At the respiratory level, our research group set the stage in evidencing a respiratory benefit after acute cervical SCI and OEC transplantation [1].

In the present report, nasal OEC transplantation was performed in conditions close to clinical situations, i.e. after a chronic contusion/compression of the cervical spinal cord [2]. We used a rat model that mimics the mechanisms encountered after a C2 cervical contusion/compression that induces a persistent hemi-diaphragmatic paralysis [3]. The respiratory rat model has been used since it has now been established that the rodent constitutes an appropriate preclinical model for treating spinal cord injury, at least for respiratory dysfunction [4]. In addition, the therapeutic efficiency of nasal OECs injection within the injured spinal cord was assessed using a delayed transplantation (2 weeks post-contusion).

Functional recovery was quantified with respiratory behavior tests, diaphragmatic electromyography and neuro-electrophysiological recording of the phrenic motoneurons while axogenesis was evaluated using immunohistochemistry. We show that 3 months post-transplantation (i.e. 3.5 months post-injury), nasal OECs could increase the incidence of neuropathic pain and worsen the neurological outcomes.


CO15-003–EN

Stem cell therapies in SCI
F. Perrin
Department of Neuroscience, Laboratory: Integrative Biology of Neurodegeneration, Faculty of Medicine, University of the Basque Country, Campus de Leioa, Ba Sarrinoa, 48940 Leioa, Spain

Keywords: Spinal cord injury; Transplantation; Stem cells

Neurological diseases are often due to a loss of cells and/or interruption of neuronal circuits. Moreover, the central nervous system, thus the spinal cord, has a limited ability to regenerate spontaneously. Stem cells (SC) are not only able to self-renew but also to produce all cell types. Their transplantation into the injured spinal cord is thus considered as a therapeutic strategy with the final goal of reducing or even aborting symptoms. Ideally, the CS could be used to generate new neurons to replace those that were lost. In SCI, the simple replacement is not sufficient to restore lost functions; new neurons indeed need to reconnect to their intra-or extra-medullary targets.

It seems, at least in a near future, more feasible to use cell transplantation to protect dying neurons, to promote their survival, and possibly to stimulate their regrowth. Cell transplants already performed in humans have unfortunately brought disappointing results. Parallel studies in animals and humans show that cell transplants could increase the incidence of neuropathic pain and worsen the neurological outcomes.

doi:10.1016/j.rehab.2011.07.177

CO15-004–EN

Spinal repair and olfactory ensheathing cells
P. Gauthier a,*, J.C. Stamegna a, P. Rega b, V. Rossi a, M.S. Felix a, J. Roux-Peyronnet a, F. Feron b, V. Matarazzo a

a CRN2M, CNRS UMR6231, équipe MP3-respiration: maturation, plasticite, physiologie et pathologie de la respiration, faculté sciences et techniques St-Jérôme, université Paul-Cézanne, 13397 Marseille, France
b IUFM, 2université de Provence, Marseille, France

c NICN, CNRS UMR 6184, université de la méditerranée, 13344 Marseille, France

*Corresponding author.

Keywords: High cervical cord injury; Breathing; Diaphragm; Transplantation; Olfactory ensheathing cells

Never before have there been so many clinical trials and human studies examining a wide range of therapeutic approaches for the treatment of spinal cord injury (SCI). The therapeutic interventions include: 1) drugs to limit the degree of secondary cell damage after the primary mechanical trauma of SCI, 2) monoclonal antibodies to promote axonal sprouting and neuroplasticity, 3) cell transplants to replace lost neural cells, and 4) activity dependent rehabilitation to facilitate functional recovery. The current status for each of these therapeutic approaches, as well as the strengths and limitations (benefits and risks) for each type of intervention will be summarized. Potential therapeutic options for the future will also be discussed, including combination treatments. With increased access to scientific and medical information via the Internet, patients are now very well informed. Consequently, all scientists and clinicians need to answer a wider scope of questions, ranging from fundamental cell biology to the many claims for clinical benefits from a seemingly endless number of treatment options. In brief, all biomedical researchers and health care professionals must now be competent knowledge translators. This means scientists and clinicians must be able to critically evaluate the quality and strength of evidence provided by different types of preclinical discoveries and human studies, as well as their realistic prospect for clinical application. In brief, human studies without appropriate control data and blinded assessments are not pivotal clinical trials and will not validate an intervention as a treatment. Payment (by a subject) for an experimental treatment automatically means it is not a clinical trial, as the investigator has a financial incentive (i.e. a bias). The optimal foundations for an ideal clinical trial program are difficult to guarantee, but several fundamental factors will be reviewed.


CO15-005–EN

An update on multiple sclerosis physiopathology
D. Laplaud
Inserm UMR643, 302, boulevard J.-Monnet, 44093 Nantes, France

Keywords: Multiple sclerosis; Immunology; Physiopathology; T lymphocyte; B lymphocyte

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) mainly affecting young adults and responsible for demyelinated patches within the white matter. The existence of an animal model, the experimental acute encephalomyelitis (EAE) based on the immunization of an animal with a myelin peptide or protein allowed a better understanding of the cellular and molecular actors playing a role in the MS lesions. Thus, peripheral activation of CD4+ autoreactive T lymphocytes appeared to be a key phenomenon in the human disease. However, the animal model presents many shortcomings in explaining the pathophysiology of MS. Human studies on the blood, cerebrospinal fluid or biopsy/autopsic samples are therefore required to better understand the lesion formation in MS. These studies have thus showed that CD8+ T lymphocytes rather than CD4+ T cells probably had a crucial role in MS injury. More recently, the involvement of B cells has been demonstrated. Taken together, from an immunological point of view, the disease appears more complex than expected. Finally, recent advances in the field of genetics helped discover about 50 genes involved in the occurrence of the disease, the majority of them having a role in the immune system. Nevertheless, there are still many discoveries to be made to modelize MS lesions, in particular the discovery of the antigens responsible for the disease. Indeed while the classical hypothesis of the emergence of MS is a peripheral immunization against CNS antigens, some